12 / 66
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 32, No 3, May/June 2021
122
AFRICA
age in cardiogenic stroke with low CHADS2 scores.
Heart Rhythm
2013;
10
(6): 921–925.
9.
Manning WJ, Weintraub RM, Waksmonski CA, Haering JM, Rooney
PS, Maslow AD,
et al
. Accuracy of transesophageal echocardiography
for identifying left atrial thrombi: a prospective, intraoperative study.
Ann Intern Med
1995;
123
(11): 817–822.
10. Hensey M, O’Neill L, Mahon C,
et al
. A review of the anatomical
and histological attributes of the left atrial appendage with descrip-
tive pathological examination of morphology and histology.
J Atrial
Fibrillation
2018;
10
(6).
11. Glotzer TV, Hellkamp AS, Lee KL,
et al
. CHA
2
DS
2
-VASc and CHADS
2
scores predict adverse clinical events in patients with pacemakers and
sinus node dysfunction independent of atrial fibrillation.
Can J Cardiol
2015;
31
(8): 1004–1011.
12. Willens HJ, Gómez-Marín O, Nelson K, DeNicco A, Moscucci M.
Correlation of CHADS
2
, and CHA
2
DS
2
-VASc scores with transesopha-
geal echocardiography risk factors for thromboembolism in a multieth-
nic United States population with nonvalvular atrial fibrillation.
J Am
Soc Echocardiogr
2013;
26
(2): 175–184.
13. Kizawa S, Ito T, Akamatsu K,
et al
. Chronic kidney disease as a possible
predictor of left atrial thrombogenic milieu among patients with nonval-
vular atrial fibrillation.
Am J Cardiol
2018;
122
(12): 2062–2067.
14. Keller K, Geyer M, Münzel T,
et al
. Impact of atrial fibrillation on
in-hospital mortality of ischemic stroke patients and identification of
promoting factors of atrial thrombi-Results from the German nation-
wide inpatient sample and a single-center retrospective cohort.
Medicine
2019;
98
(4): e14086–e14086.
15. Pant R , Patel M , Garcia-Sayan E ,
et al
. Impact of B-type natriuretic
peptide level on the risk of left atrial appendage thrombus in patients
with nonvalvular atrial fibrillation: A prospective study.
Cardiovasc
Ultrasound
2015;
14
(1): 1–7.
16. Wazni OM, Tsao HM, Chen SA, Chuang HH, Saliba W, Natale A,
Klein AL. Cardiovascular Imaging in the management of atrial fibrilla-
tion.
J Am Coll Cardiol
2006;
48
(10): 2077–2084.
17. Leung DY, Davidson PM, Cranney GB, Walsh WF. Thromboembolic
risks of left atrial thrombus detected by transesophageal echocardio-
gram.
Am J Cardiol
1997;
79
(5): 626–629.
18. Budge LP, Shaffer KM, Moorman JR, Lake DE, Ferguson JD,
Mangrum JM. Analysis of
in vivo
left atrial appendage morphology in
patients with atrial fibrillation: a direct comparison of transesophageal
echocardiography, planar cardiac CT, and segmented three-dimensional
cardiac CT.
J Interv Card Electrophysiol
2008;
23
(2): 87–93.
19. Clark CB, Telles Garcia NA, Hackett Renner C, Ryan SM. Correlation
of left atrial appendage ejection velocities with the CHADS
2
and
CHA
2
DS
2
-VASc scores.
Echocardiography
2016;
33
(8): 1195–1201.
20. Douros A, Renoux C, Yin H,
et al
. Concomitant use of direct oral
anticoagulants with antiplatelet agents and the risk of major bleeding
in patients with non-valvular atrial fibrillation.
Am J Med
2019;
132
(2):
191–199.
21. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S,
et al
.
Guidelines for the management of atrial fibrillation.
Eur Heart J
2010;
31
(19): 2369–2429.
22. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen
KA,
et al
. 2011 ACCF/AHA/HRS focused updates incorporated
into the ACC/AHA/ESC 2006 guidelines for the management of
patients with atrial fibrillation: a report of the American College of
Cardiology Foundation/American Heart Association Task Force on
Practice Guidelines developed in partnership with the European Society
of Cardiology and in collaboration with the European Heart Rhythm
Association and the Heart Rhythm Society.
J Am Coll Cardiol
2011;
57
(11): e101–198.
23. Deitelzweig S, Farmer C, Luo X,
et al
. Comparison of major bleeding
risk in patients with non-valvular atrial fibrillation receiving direct oral
anticoagulants in the real-world setting: a network meta-analysis.
Curr
Med Res Opin
2017: 1–30.
24. Yarmohammadi H, Varr BC, Puwanant S, Lieber E, Williams SJ,
Klostermann T,
et al
. Role of CHADS
2
score in evaluation of thrombo-
embolic risk and mortality in patients with atrial fibrillation undergoing
direct current cardioversion (from the ACUTE trial substudy).
Am J
Cardiol
2012;
110
(2): 222–226.
25. Frühauf M, Eitel C, Bollmann A, Piorkowski C, Wetzel U, Schliephake
F, Arya A. Should transesophageal echocardiography be done in all
patients who underwent catheter ablation of atrial fibrillation? A
case report and review of the literature.
Clin Res Cardiol
2010;
99
(2):
125–128.
26. Parikh MG, Aziz Z, Krishnan K, Madias C, Trohman RG. Usefulness
of transesophageal echocardiography to confirm clinical utility of
CHA
2
DS
2
-VASc and CHADS
2
scores in atrial flutter.
Am J Cardiol
2012;
109
(4): 550–555.
27. Providência R, Botelho A, Trigo J, Quintal N, Nascimento J, Mota P,
Leitão-Marques A. Possible refinement of clinical thromboembolism
assessment in patients with atrial fibrillation using echocardiographic
parameters.
Europace
2012;
14
(1): 36–45.
28. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen
J,
et al
. Validation of risk stratification schemes for predicting stroke and
thromboembolism in patients with atrial fibrillation: nationwide cohort
study.
Br Med J
2011;
342
: 124.
29. Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A compari-
son of risk stratification schemes for stroke in 79884 atrial fibrillation
patients in general practice.
J Thromb Haemost
2011;
9
(1): 39–48.
30. Poli D, Lip GY, Antonucci E, Grifoni E, Lane D. Stroke risk stratifica-
tion in a «real-world» elderly anticoagulated atrial fibrillation popula-
tion.
J Cardiovasc Electrophysiol
2011;
22
(1): 25–30.
31. Levine GN, Bates ER, Bittl JA, Brindis RG, Smith SC. 2016 ACC/AHA
guideline focused update on duration of dual antiplatelet therapy in
patients with coronary artery disease: a report of the American College
of Cardiology/American Heart Association Task Force on clinical
practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline
for percutaneous coronary intervention, 2011 ACCF/AHA guideline
for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/
PCNA/SCAI/STS guideline for the diagnosis and management of
patients with stable ischemic heart disease.
Circulation
2016;
82
(4):
E266–E355.
32. Karthikeyan G, Eikelboom JW. The CHADS
2
score for stroke risk
stratification in atrial fibrillation – friend or foe?
Thromb Haemost
2010;
104
(1): 45–48.
33. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM,
Prineas RJ, Folsom AR. Incidence of atrial fibrillation in whites and
African-Americans: the Atherosclerosis Risk in Communities (ARIC)
study.
Am Heart J
2009;
158
(1): 111–117.
34. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK,
Udaltsova N,
et al
. A new risk scheme to predict ischemic stroke and
other thromboembolism in atrial fibrillation: The ATRIA study stroke
risk score.
J Am Heart Assoc
2013;
2
(3): e000250.